Ibogaine Research and Policy News
The ibogaine research and policy news that matters, with primary sources. Updated October 2026.
The ibogaine research and policy news that matters, with primary sources. Updated October 2026.
The FDA opened a request for information on how ibogaine clinical trials should be designed and run, following the April 2026 executive order. Comments are open until November 20, 2026. It does not change ibogaine’s Schedule I status or open any treatment route in the US yet.
Source: FDAAn April 2026 executive order on accelerating treatments for serious mental illness directs the FDA and DEA to establish a Right to Try access pathway for psychedelic drugs including ibogaine compounds, and commits $50 million in federal funding to ibogaine research. It does not legalize ibogaine, which remains Schedule I, and no domestic treatment route has opened yet, but it is the strongest federal signal to date.
Source: The White HouseThe State of Texas awarded $50 million to UTMB Health, with UTHealth Houston, to lead IMPACT, a two-year multicenter clinical trial of ibogaine for PTSD, addiction and cognitive trauma. It is the largest public investment in ibogaine research to date and the clearest sign that US medical acceptance is being seriously tested.
Source: UTMB HealthA Stanford Medicine study published in Nature Medicine followed 30 US special-operations veterans with traumatic brain injury who received ibogaine with magnesium at a Mexican clinic. The cohort averaged an 88 percent reduction in PTSD symptoms with no serious cardiac events. The study was open-label and uncontrolled, so it is promising evidence, not proof.
Source: Stanford MedicineArizona, Kentucky, Nevada, New York, Oregon, Texas and Washington all introduced ibogaine access or research legislation in 2025, per the Legislative Analysis and Public Policy Association. Texas became the first to fund trials at scale.
Source: LAPPAA preprint analyzing outcomes across international clinics reports substantially lower death rates under modern screening and monitoring protocols than historical estimates, with risk concentrated in opioid-dependent patients. The data is self-reported by clinics and not yet peer reviewed, so treat it as directional.
Source: Research Square (preprint)21 questions to ask any ibogaine clinic, with what a good answer sounds like, as a printable PDF. One email a month, unsubscribe any time.